You are here

  • Home
  • Archive
  • Volume 11, Issue 2
  • KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group

Article metrics

Article menu
Immunotherapy biomarkers
Original research
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children’s Oncology Group

 

Online download statistics by month:

Online download statistics by month: February 2023 to February 2026

AbstractFullPdf
Feb 202323423472
Mar 2023232237137
Apr 202315015060
May 2023909038
Jun 2023848429
Jul 2023898936
Aug 20231041049
Sep 2023686810
Oct 2023585819
Nov 2023676821
Dec 2023575832
Jan 2024585842
Feb 2024585833
Mar 2024667193
Apr 2024606040
May 2024606043
Jun 2024474629
Jul 2024545634
Aug 2024343319
Sep 2024464630
Oct 2024383831
Nov 2024424425
Dec 2024555723
Jan 2025444542
Feb 202511311439
Mar 2025424240
Apr 2025808047
May 2025515240
Jun 2025262621
Jul 2025110
Feb 2026110
Total220922281134